Sunitinib: bridging present and future cancer treatment.
about
Autocrine CSF-1 and CSF-1 receptor coexpression promotes renal cell carcinoma growth.Differential cytotoxicity induced by the Titanium(IV)Salan complex Tc52 in G2-phase independent of DNA damage.Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study.Sunitinib (SUTENT) for the treatment of metastatic renal cell carcinoma.Synergistic effect between cisplatin and sunitinib malate on human urinary bladder-cancer cell lines.MicroRNA-566 activates EGFR signaling and its inhibition sensitizes glioblastoma cells to nimotuzumab.CSF1R copy number changes, point mutations, and RNA and protein overexpression in renal cell carcinomas.Targeting lymphangiogenesis after islet transplantation prolongs islet allograft survival.
P2860
Q35653176-855E33F8-4C96-425E-97F0-33924617563DQ36076728-22F07FBE-9A76-43A2-BCEE-D8B5CC5D73C7Q36816946-9FB825AE-98A3-4AB7-BC7E-5F123B59C878Q37301234-3160801F-F729-4C55-B517-EDFBC945AD59Q37392963-47C3FBC4-3A2C-46EC-A16B-29E1078BD1ACQ37723702-C84FA55B-219B-47B0-9D08-CD65D13718FFQ39986346-FA077E17-EAE0-4DFA-81B0-77E5204B4BB3Q42272995-07020470-E311-4C42-9FD2-CAE8D472EF5F
P2860
Sunitinib: bridging present and future cancer treatment.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Sunitinib: bridging present and future cancer treatment.
@en
type
label
Sunitinib: bridging present and future cancer treatment.
@en
prefLabel
Sunitinib: bridging present and future cancer treatment.
@en
P2093
P356
P1433
P1476
Sunitinib: bridging present and future cancer treatment
@en
P2093
P304
P356
10.1093/ANNONC/MDM221
P478
18 Suppl 6
P577
2007-06-01T00:00:00Z